liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The role of biphosphonates in the management of thalassemia-induced osteoporosis: a systematic review and meta-analysis
Naval Hosp Athens, Greece.
Univ Athens, Greece; Univ Athens, Greece; Univ Athens, Greece.
Region Östergötland, Heart and Medicine Center, Department of Clinical Physiology in Linköping.
Hippocration Gen Hosp, Greece.
Show others and affiliations
2018 (English)In: HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, ISSN 1109-3099, Vol. 17, no 2, p. 153-166Article, review/survey (Refereed) Published
Abstract [en]

Thalassemia Major (TM) is a clinical entity with a high prevalence of low bone mass. The aim of the present study was to perform a meta-analysis of all available data on the role of bisphosphonates (BPs) in the therapy of thalassemia major-induced osteoporosis. The PRISMA recommendations for reporting systematic reviews and meta-analyses were used to guide the present study. We searched PubMed and the Cochrane Central Register of Controlled Trials (CENTRAL) through March 31, 2017 for articles related to thalassemia and BPs. To meta-analytically synthesize the primary endpoint, we used the standardized mean difference (SMD) after Hedgess g transformation under the scenario of a random effects model. Heterogeneity across studies was examined using the I (2) statistic. Nine randomized controlled trials (RCTs) containing original data were included in this review. Three studies were performed in Italy, one in Australia, three in Greece, one in Cyprus, and one in China. The BPs investigated included zoledronate, alendronate, pamidronate, clodronate, and neridronate. Zoledronate and alendronate showed a tendency to perform best as compared to neridronate and the placebo effect with respect to femoral neck, lumbar spine, total hip, and total body in terms of bone mass density (g/cm(2)). BPs and in particular, zolendronate, were quite effective in the treatment of osteoporosis. These findings suggested that bisphosphonates are still a front-line treatment of osteoporosis in TM. However, to draw more meaningful and significant conclusions for the use and efficacy of BP in TM, larger and more complete RCTs should be conducted.

Place, publisher, year, edition, pages
SPRINGER , 2018. Vol. 17, no 2, p. 153-166
Keywords [en]
Osteoporosis; Bone mineral density; Bisphosphonates; beta-thalassemia; Zolendronic acid
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:liu:diva-149877DOI: 10.1007/s42000-018-0019-3ISI: 000438142000002PubMedID: 29858849OAI: oai:DiVA.org:liu-149877DiVA, id: diva2:1236414
Available from: 2018-08-02 Created: 2018-08-02 Last updated: 2018-08-02

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Tsartsalis, Dimitrios
By organisation
Department of Clinical Physiology in Linköping
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 26 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf